S

Signadori Bio

Latest funding round: 12 M$

S

• City : Paris
• Round : Seed
• Sector : Health

Signadori Bio develops an in vivo immunotherapy based on monocyte reprogramming to treat solid tumours. The preclinical biopharmaceutical company aims to improve the innate immune system’s antitumour activity.